Stocks
Neurocrine Biosciences (NBIX) Debt/EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | -0.77 | -1.16 | -1.24 | -2.75 | -1.45 | -1.58 | |||
| Changes by years, y/y, % | -89% | +50% | +7% | +122% | -47% | -27.2% | |||
Neurocrine Biosciences. Debt/EBITDA
Neurocrine Biosciences. Debt/EBITDA, changes, %
Neurocrine Biosciences (NBIX) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| Debt/EBITDA | -2.37 | -1.49 | -1.36 | -1.31 | -1.58 | -1.58 | ||
| Changes by years, y/y, % | -32% | -47% | -39% | -45% | -34% | |||
| Changes by quarters, q/q, % | -1% | -37% | -8% | -4% | +20% | |||
